DTNBP1 (dystrobrevin binding protein 1) remains one of the top candidate genes in schizophrenia. Reduced expression of this gene and the protein it encodes, dysbindin-1, has been reported in the dorsolateral prefrontal cortex (DLPFC) of schizophrenia cases. It has not been established, however, if all dysbindin-1 isoforms are reduced in the DLPFC or if the reduction is associated with reduced DTNBP1 gene expression. Using Western blotting of whole-tissue lysates of the DLPFC with antibodies differentially sensitive to the three major isoforms of this protein (dysbindin-1A, -1B, and -1C), we found no significant differences between our schizophrenia cases and matched controls in dysbindin-1A or -1B, but did find a mean 46% reduction in dysbindin-1C in 71% of 28 case-control pairs (p = 0.022). This occurred in the absence of the one DTNBP1 risk haplotype for schizophrenia reported in the US and without alteration in levels of dysbindin-1C transcripts. Conversely, the absence of changes in the dysbindin-1A and -1B isoforms was accompanied by increased levels of their transcripts. We thus found no correspondence between alterations in dysbindin-1 gene and protein expression, the latter of which might be due to posttranslational modifications such as ubiquitination. Reduced DLPFC dysbindin-1C in schizophrenia probably occurs in PSDs, where we find dysbindin-1C to be heavily concentrated in the human brain. Given known postsynaptic effects of dysbindin-1 reductions in the rodent homolog of the prefrontal cortex, these findings suggest that reduced dysbindin-1C in the DLPFC may contribute to cognitive deficits of schizophrenia by promoting NMDA receptor hypofunction.
Introduction
Since the initial report of Straub et al. in 2002 , 1 many studies have found that genetic variation in DTNBP1 (dystrobrevin binding protein 1) is associated with schizophrenia as reviewed by several investigators. [2] [3] [4] Indeed, DTNBP1 remains among the top candidate genes for the disorder according to recent analyses. 5, 6 DTNBP1 risk SNPs and haplotypes have been associated with a diverse group of cognitive deficits, which collectively form a core feature of schizophrenia. [7] [8] [9] Even in individuals without psychiatric illness, cognitive performance is worse in carriers of DTNBP1 risk SNPs than in non-carriers. [10] [11] [12] The same is true for Sz cases carrying such SNPs. They show greater decline in general cognitive ability from a premorbid to a clinical state, 13 lower general cognitive ability in the clinical state itself, 10 lower scores on verbal, performance, and full-scale IQ tests on the
Wechsler Adult Intelligence Scales-Revised, 14 , 15 deficits on a spatial working memory task and a Go NoGo attentional response task, 16 and poor performance on Trail-Making Tests A and B.
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DTNBP1 encodes the first known member of the dysbindin protein family, dysbindin-1, 4 which is expressed in diverse neuronal populations throughout the brain. 4, 18, 19 It is found in neuronal cell bodies, as well as pre-and post-synaptic sites in areas commonly affected in schizophrenia, such as the hippocampal formation and neocortex. 4, 19 Postmortem studies on schizophrenia cases have respectively). We began to study these isoforms to determine which account for the observed dysbindin-1 reductions in schizophrenia. This is important because the isoforms are expected to play different neuronal roles as indicated by their differential distribution in synaptic and nuclear tissue fractions. 4, 21 We focus here on the DLPFC not only because that area is commonly affected in schizophrenia, 22, 23 but also because all the cognitive tasks on which carriers of DTNBP1 risk SNPs perform poorly (see above) are mediated in part by the DLPFC. A role for the DLPFC in these cognitive tasks is evident in studies identifying brain regions involved in general cognitive ability, 24, 25 IQ, [25] [26] [27] spatial working memory, [28] [29] [30] and mental flexibility. 31, 32 The present study is the first full report on dysbindin-1 protein expression and transcript-specific dysbindin-1 gene expression in the same schizophrenia cases. In such cases, we specifically investigated whether dysbindin-1 protein expression in the DLPFC is altered in an isoform-specific manner and if any such alteration is correlated with transcript-specific dysbindin-1 gene expression. We also tested if any observed alterations in dysbindin-1 isoforms or their transcripts occur in the absence of the DTNBP1 risk haplotype reported in a U.S. population by Funke et al. 33 
Materials and methods

Research Design and Subjects
A matched-pairs design was used to compare fresh-frozen DLPFC tissue from 28 Caucasian schizophrenia cases with 28 non-psychiatric Caucasian controls matched for sex and age within 5 years (Table 1) . With the sole exception of a schizophrenia case with a 30 h postmortem interval (PMI) retained due to good protein and RNA preservation, all the cases had low PMIs (mean ± SD = 11.9 ± 5.4 h for schizophrenia cases and 7.7 ± 3.8 h for controls). The schizophrenia cases had participated in a longitudinal study of prospectively diagnosed subjects approved by an Institutional Review Board at the University of Pennsylvania and 35 as determined in consensus conferences following review of medical records, direct clinical assessments of the patients, and interviews with care providers.
Place Table 1 about here
Dysbindin-1 antibodies
Dysbindin-1 isoforms in human DLPFC lysates were characterized using three polyclonal rabbit antibodies developed for use by our research group: Oxford PA3111A, UPenn 329, and UPenn 331 ( Figure 1B ). PA3111A was generated in Dr. Derek Blake's laboratory at the University of Oxford. It was raised against a long C-terminus segment of mouse dysbindin-1 (amino acids 196-352) and has been characterized in earlier reports 4, 18, 19 UPenn 329 was generated by Sigma Aldrich (St. Louis, MO, USA) against a synthetic peptide consisting of aa 313-326 in the C-terminus region of human dysbindin-1A and -1C (NCBI accession nos.
NP_115498 and NP_898862, respectively). UPenn 331 was also generated by Sigma Aldrich, but against a synthetic peptide consisting of aa 24-37 in the Nterminus region of human dysbindin-1A and -1B (NCBI proteins NP_115498 and NP_898861, respectively).
Quantification of DTNBP1 isoforms by Western immunoblotting
Tissue was obtained at autopsy from the DLPFC (Brodmann areas 9 +46) and stored at -80°C ( DTNBP1 mRNA levels were measured using quantitative real-time polymerase chain reactions (qPCR) with primer pairs specified in Table S1 . We for the housekeeping genes are also specified in Table S1 .
Four primer pairs were designed to target DTNBP1 transcripts (Table S1 and Figure 
DTNBP1 genotyping
DNA was obtained from fresh frozen brain tissue using the Gentra PUREGene cell kit (Qiagen, Valencia, CA, USA). Using a TaqMan 5' exonuclease allelic discrimination assay (Applied Biosystems), the DNA was genotyped for a SNP
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(P1578 = rs1018381) tagging a 6-SNP DTNBP1 risk haplotype for schizophrenia reported in a case-control study on US Caucasians. 33 
Data analysis
Western blotting. Comparisons of dysbindin-1 levels were naturally complicated by the fact that the number of samples exceeded the loading lanes of a single gel.
We initially tried solving this problem by expressing optical density (OD) of bands as a percentage of one or two reference samples run on all blots. We discovered, however, that calibrating optical density measurements to reference samples did not yield values as reliable across blots as pair-wise ratios of each schizophrenia case to its matched control run on the same blot, as previously noted by Albert et al. 40 We thus used two approaches. For analyses which did require comparison across blots (i.e., correlation of age, brain pH, and PMI with dysbindin-1 isoform levels in all samples), the OD of each band in a Western blot was divided by that of the reference sample (or samples) run on the same blot after normalizing for loading variations using β-actin levels. Averages of these values on the original and replication blots were used in correlational analyses. For analyses which did not require comparison across blots (i.e., Wilcoxon tests of differences within case-control pairs run on the same blot), we determined the OD for a dysbindin-1 isoform in each schizophrenia case compared to its matched control run in an adjacent lane of the same blot using (a) raw OD data, (b) OD data normalized to β-actin, and (c) OD data normalized to density of MemCode staining. These OD ratios obtained from data on the original and replication blots were averaged and then log 2 transformed such that a zero ratio reflected no difference between a schizophrenia case and its matched control, a negative ratio reflected a decrease in the schizophrenia case, and a positive ratio reflected an increase in that case.
The log transformation permits use of the Wilcoxon signed ranks test for ratio data, because the log of a ratio between two values X/Y = logX -logY.
qRT-PCR.
Since all samples to be compared were run at the same time in one 384-well plate, data analysis was simplified compared to that for the Western blotting data. Real-time PCR data acquisition and analysis were performed using SDS version 2.0 software (Applied Biosystems). Data points were omitted if they varied more than 1% from the mean of the triplicate samples based on raw cycle threshold values. In each experiment, the standard curve had a coefficient of determination (R 2 ) > 0.996 and a slope between -3.32 and -3.57, which indicated an amplification efficiency of 91-100%. Negative controls comprising no-template cDNA yielded no detectable signal. An expression value for each reaction was quantified against a standard curve constructed from serial dilutions of the pooled cDNA. The relative expression value of dysbindin-1 mRNA was normalized to a geometric mean of the three internal control genes performed as suggested by
Vandesompele et al. 41 Statistical analyses were performed with GraphPad Prism 3.0 software (GraphPad Software, La Jolla, CA, USA). Unpaired t-tests were used to assess statistical differences between schizophrenia cases and controls in demographic and autopsy variables (age, brain pH, and PMI). For Western blotting data, the non-parametric Wilcoxon signed-rank test was used to test if the log transformed pair-wise ratios were statistically different from the hypothetical median value of zero representing no significant differences between schizophrenia and control cases. For qRT-PCR data, the Wilcoxon signed-rank and unpaired t tests were used to test differences in PCR products between cases and matched controls.
For comparison of case-control ratios of proteins and of transcripts, the MannWhitney U test was used. The p values reported are two-tailed with p less than 0.05 considered significant.
Results
Dysbindin-1 Isoforms in DLPFC
According to NCBI's Reference Sequence (RefSeq) database, a highly curated transcript collection, 42 there are three validated splice variants of human DTNBP1 mRNA among sixteen deduced DTNBP1 splice variants identified in the AceView database (http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html). These appear to be the most commonly expressed transcripts based on the number of cDNA clones available for their reconstruction. They encode dysbindin-1A, -1B and -1C (NCBI accession numbers NP_115498, NP_898861, and NP_898862, respectively). These proteins are the known isoforms of dysbindin-1, which along with dysbindin-2 and -3, constitute the dysbindin protein family, all of whose members share a still poorly understood dysbindin domain (DD). 4 The length and component parts of dysbindin-1 isoforms are indicated in Figure 1A . All have a coiled coil domain (CCD) important for certain protein-protein interactions but absent in dysbindin-2 and -3. Isoform A (351 aa in humans) is the full-length dysbindin-1 with a PEST domain at its C-terminus. Isoform B (303 aa), which is not expressed in the mouse, differs from isoform A only in its C-terminus region, which is shorter and lacks a PEST domain. In contrast, isoform C (270 aa) differs from isoform A only in the absence of an N-terminus region in front of its CCD.
Place Figure 1 about here
Using Oxford PA3111A, a well validated polyclonal antibody generated against the C-terminus region of dysbindin-1A ( Figure 1B) , 18, 19 we consistently detected three bands in Western blots of human DLPFC lysates at a dilution of 1:1000 ( Figure 1C ), as we have in synaptosomal fractions of the human DLPFC, (Talbot et al., submitted) . In an earlier study, 19 we detected only two bands with PA3111A in lysates of human brain tissue. Detection of three bands with that antibody in our current studies may reflect use of larger protein samples (50 μg vs. 20-40 μg), higher percentage gels (12% vs. 10%), and more sensitive chemiluminescence detection kits. The three bands lay at about 48, 36, and 32 kDa ( Figure 1C ). None of these bands were found when the antibody had been preadsorbed with the immunogen or with full-length dysbindin (i.e., dysbindin-1A).
The heaviest band at about 48 kDa was readily identified as full-length dysbindin-1, which has been reported to run at about 50 kDa. 18, 19, 43 This is greater than the predicted 40 kDa mass of dysbindin-1A, probably due to its acidic nature As shown in Figure 1C , the identity of the 48, 36, and 32 kDa bands seen with Oxford PA3111A were confirmed by results with other polyclonal antibodies.
These were raised against synthetically derived peptide sequences in full-length dysbindin-1. One (UPenn 329), was raised against a 14 aa C-terminus sequence (aa 313-326) shared by dysbindin-1A and -1C, while the other (UPenn 331) was raised against a 14 aa N-terminus sequence (aa 24-37) shared by dysbindin-1A
and -1B ( Figure 1B) . As the location of their immunogens predicted, UPenn 329 recognized the top and bottom bands (i.e., dysbindin-1A and -1C), while UPenn 331 recognized the top and middle bands (i.e., dysbindin-1A and -1B, Figure 1C ).
Even at a dilution of 1:6000, however, UPenn 331 had an unusually high avidity for dysbindin-1B with only low avidity for dysbindin-1A and no detectable avidity for dysbindin-1C ( Figure 1C ). The failure of UPenn 331 to recognize dysbindin-1C is expected since its immunogen lies in the N-terminus region of dysbindin-1 absent in dysbindin-1C. As these results indicate, UPenn 331 at the dilution used is a very sensitive and largely selective antibody for dysbindin-1B. It thus yields data complementary to Oxford PA3111A, which has a high avidity for dysbindin-1A and -1C but apparently much lower avidity for dysbindin-1B judging from the weaker middle band seen in PA3111A blots ( Figure 1C ). For these reasons, we used Oxford PA3111A to detect dysbindin-1A and -1C, but UPenn 331 to detect dysbindin-1B.
-----------------------------------------------------------------------------------------Place Figure 2 about here -----------------------------------------------------------------------------------------
Dysbindin-1 Isoform Expression in DLPFC of Schizophrenia vs. Control Cases
Representative results of Western blotting for dysbindin-1 isoforms in DLPFC of schizophrenia cases and matched controls are shown in For dysbindin-1A, the direction (plus or minus) and magnitude of the ratios were highly inconsistent. For dysbindin-1B, the ratios were also very inconsistent in direction, and their magnitudes were generally very small. Pair-wise analyses of each schizophrenia case to its matched control with the Wilcoxon signed-rank test accordingly showed no significant differences between schizophrenia and controls in levels of these two dysbindin-1 isoforms, which was the case whether raw or normalized data were used (n = 28, W = 78, p = 0.38 for dysbindin-1A; n = 28, W = -12, p = 0.89 for dysbindin-1B).
For dysbindin-1C, however, protein levels were reduced from 12-85% in the schizophrenia cases compared to matched controls in 20 out of the 28 pairs (71.42%). Unlike the case with the other two isoforms, pair-wise ratio analysis showed that dysbindin-1C in the DLPFC was significantly reduced in the DLPFC of our schizophrenia cases by an average of 46% (n = 28, W = 202, p = 0.0221).
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Dysbindin-1 Gene Expression in DLPFC of Schizophrenia vs. Control Cases
To determine if the observed isoform-specific reduction in dysbindin-1 may be due to reductions in DTNBP1 gene expression, we measured the latter with qRT-PCR using primer pairs specific for DTNBP1 transcripts in general (DYS-95 and -
102), for DTNBP1 transcript d (DYS-d) encoding dysbindin-1B, and for DTNBP1
transcript e (DYS-e) encoding dysbindin-1C (see Table S1 ). Figure 4A -
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DTNBP1 Genotyping and Its Relation to DTNBP1 Gene and Protein Expression
Only 2 controls and 2 schizophrenia cases were found to carry the rare allele of the P1578 SNP in DTNBP1 tagging a risk haplotype for schizophrenia in a US cohort. 33 As a result, we were unable to test the effect of this haplotype on either gene or protein expression of DTNBP1. However, we were able to test if the observed differences between schizophrenia and control cases occurred in the absence of the haplotype. That proved to be the case. Exclusion of the case-control pairs with individuals carrying the rare allele of P1578 had no effect on the outcome of statistical analyses on dysbindin-1 isoforms or transcripts.
Consideration of Potential Confounding Variables
The observed dysbindin-1C reductions in schizophrenia cases were not readily attributed to non-diagnostic variables. Our schizophrenia and control groups had the same female/male ratio and did not differ significantly in age or brain tissue pH. While mean PMI was longer in the schizophrenia cases (11.9 ± 5.4 h) than in the controls (7.7 ± 3. 
Discussion
In this first report on dysbindin-1 isoforms in schizophrenia, we have discovered that DLPFC levels of dysbindin-1C, but not those of dysbindin-1A or -1B, are significantly altered. In particular, about 71% of our cases displayed 12-85% lower levels of disbindin-1C than did their matched controls. As detailed above, these results are not attributable to uncontrolled differences between diagnostic groups. While the present findings are based on whole-tissue lysates, we have found that dysbindin-1 is highly enriched in synaptic tissue fractions of both the mouse and human brain. This is the second study pointing to reduced dysbindin-1 as a synaptic abnormality in schizophrenia. Depending on the specific anatomic area studied, our previous immunohistochemical work with the Oxford PA3111A antibody indicated that presynaptic dysbindin-1 was reduced in a very similar proportion of schizophrenia cases compared to their matched controls. 19 Our more recent
Western blotting work on synaptosomal preparations with the antibodies used in this study show that the presynaptic reduction in the hippocampal formation is due principally to decreased dysbindin-1B associated with synaptic vesicles and that this is accompanied by a previously undetected reduction in postsynaptic dysbindin-1 due to a decrease in dysbindin-1C (Talbot et al., submitted). As in the DLPFC, dysbindin-1A levels were unaltered in the hippocampal formation.
There is thus growing evidence for isoform-specific dysbindin-1 reductions in schizophrenia that vary across brain areas.
The cause(s) of reduced dysbindin-1C in the DLPFC of schizophrenia cases is unknown. Using a riboprobe that would hybridize with mRNAs of all the dysbindin-1 isoforms studied here, Weickert et al. 45 found that DTNBP1 gene expression in schizophrenia cases was 15-20% lower in all DLPFC cell layers except layer IV. Using quantitative RT-PCR with primers specific for dysbindin-1 transcripts, however, we did not replicate that finding using a larger case sample of different ethnicity with far lower PMIs (i.e., 28 Caucasian schizophrenia cases with PMIs of 11.9 ± 5.4 h in this study versus 14 predominantly African-American schizophrenia cases with PMIs of 38.0 ± 21.9 h in the study of Weickert et al. 45 ).
Moreover, we found no correspondence between schizophrenia-related changes in DTNBP1 gene and protein expression in the DLPFC, both of which occurred in the absence of the one known DTNBP1 risk haplotype 33 for schizophrenia in the US. The lack of correspondence in gene and protein expression changes was striking. In the schizophrenia cases, overall levels of dysbindin-1 transcripts were elevated for unknown reasons, yet levels of the major encoded proteins were not.
Levels of transcripts specific for dysbindin-1B were increased in schizophrenia cases, but levels of the isoform itself were not. Conversely, levels of transcripts specific for dysbindin-1C were normal in the schizophrenia cases, yet levels of an increasingly large number of studies. 50, 51 It has been argued that in schizophrenia NMDA hypofunction in the parvalbumin-positive, fast-spiking interneurons of the DLPFC innervating initial axon segments of pyramidal neurons in the same brain area would reduce synchronized activity of the DLPFC and thereby disrupt processes important for working memory. 52 The DLPFC is involved in several types of working memory, including spatial working memory, 28, 29 deficits in which are among the most common cognitive impairments in schizophrenia. [7] [8] [9] Homozygous sandy mice, which lack dysbindin-1C, also display working memory deficits, 53- The two pan dysbindin-1 primers can recognize many DTNBP1 transcripts, including those for dysbindin-1A, -1B, and -1C; they differ only in recognition of minor transcripts (AceView DTNBP1 transcripts i-m) not yet detected in the DLPFC. Of the DTNBP1 transcripts currently listed on AceView, only a-e are known to be expressed in that brain area (R. Straub, personal communication).
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The B2M (beta-2-microtubulin), HPRT1 (hypoxanthine phosphoribosyl-transferase 1), and GAPDH (glyceraldehyde-3-phosphate dehydrogensase) primer sequences are described in Vandesompele 
